The aforementioned study demonstrated that the inhibition of PLK-1 significantly sensitizes cancer cells to oxaliplatin therapy, and that combined treatment with chemotherapy and PLK-1 inhibitors exhibits a synergistic effect both in vitro and in vivo, potentially opening new horizons in overcoming chemoresistance. The gene discussed is PLK1; the disease is cancer.